for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
UK Top News

Factbox: AstraZeneca's potential coronavirus vaccine

(Reuters) - Trial data for AstraZeneca AZN.L and University of Oxford's possible coronavirus vaccine could be given to regulators this year, a scientist leading the trials said on Tuesday.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

Drugmakers are racing to combat the pandemic, which has killed about 810,000 people and infected roughly 24 million.

There are no approved vaccines for COVID-19, but AstraZeneca’s vaccine is widely seen as one of the leading candidates, with reports that the United States is aiming for a fastrack approval before the November presidential election.

The company has been granted protection from future product liability claims related to the vaccine by most of the countries with which it has so far struck supply agreements, a senior executive told Reuters.

Below are the main details of the vaccine and its supply and production deals.

TYPE

PROTECTION DURATION

EXPECTED COST

TRIALS

TIMELINE

TARGET DOSES

TIE-UPS

Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Tanishaa Nadkar; Editing by Jan Harvey and Mark Potter

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up